Clinical Trials on Hepatitis C, Chronic in Mexico

Total 747 results

Hanmi Pharmaceutical Company Limited

Unknown

Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)

Chronic Hepatitis C Virus Genotype I

Mexico
Hospital General de Mexico
AbbVie

Completed

Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis

Vasculitis | Chronic Hepatitis c

Mexico
Gilead Sciences

Completed

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

HCV Infection

Mexico
Bristol-Myers Squibb

Completed

Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults

Hepatitis C

Mexico
Bristol-Myers Squibb

Withdrawn

Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults

Hepatitis C

Mexico
University of Guadalajara
Hospital Central Militar

Recruiting

Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).

Liver Cirrhosis | Hepatitis C, Chronic | Epigenetic Disorder

Mexico
University of New Mexico

Terminated

Rapid HCV RNA Testing and LInkage to Care (TEAL)

Hepatitis C, Chronic

United States
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.

Hepatitis C, Chronic

Mexico
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

Chronic Hepatitis C

United States
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Chronic Hepatitis C Infection

United States, Spain, United Kingdom, Canada, Germany, France, Austria, Poland, Belgium, Czech Republic, Italy
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Chronic Hepatitis C

Korea, Republic of, United States, Spain, Canada, France, Australia, Israel, Singapore, Thailand, Malaysia, Sweden, Belgium, Germany, Taiwan, Poland, Argentina, India, Puerto Rico, Brazil, Mexico, United Kingdom
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
University of Florida
Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie

Completed

Study of Oral Treatments for Hepatitis C (PRIORITIZE)

Chronic Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Chronic Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Chronic Hepatitis C Virus

United States
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (DIMENSION)

Chronic Hepatitis C Infection

France, Germany, United States, Spain, Canada, Argentina, Mexico, Belgium, Italy, Russian Federation, United Kingdom, Poland
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (FUSION)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Chronic Hepatitis C

France, United States, Puerto Rico
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Chronic Hepatitis C

United States, Spain, Canada, France, Australia, Italy, Israel, Poland, United Kingdom, Germany, Czech Republic, Romania, Austria, India, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Gilead Sciences

Terminated

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Hepatitis C Virus Infection

France, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Hepatitis C

Argentina, Australia, Belgium, France, Germany, Italy, United States, Canada, Spain, Mexico, Austria, Poland, Netherlands, Korea, Republic of, Puerto Rico, New Zealand, Finland, Greece, Romania
Gilead Sciences

Completed

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection (NEUTRINO)

Chronic Hepatitis C

United States, Puerto Rico
Proteus Digital Health, Inc.

Unknown

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence (DASH)

Hepatitis C, Chronic | Nonadherence, Patient

United States
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Gilead Sciences

Terminated

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

United States, United Kingdom, Germany, Canada, Puerto Rico, Poland
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Hepatitis C, Chronic

United States, Canada
Gilead Sciences

Completed

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 (ATOMIC)

Hepatitis C, Chronic

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Hepatitis C, Chronic

France, Germany, United States, New Zealand
Hoffmann-La Roche

Completed

A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

Hepatitis C, Chronic

Australia, Canada, Mexico, New Zealand, Thailand, Argentina
Gilead Sciences

Completed

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Germany, Sweden, Switzerland, Turkey, Greece, Taiwan, Estonia, Slovakia, Italy, Romania, Lithuania, Serbia, Portugal, Egypt, Pakistan, Mexico, Peru, Lebanon, United States, Argentina, Chile, Kuwait, Latvia, Macedonia, The... and more
Hoffmann-La Roche

Completed

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

France, Germany, United States, Spain, Canada, Austria, United Kingdom, Puerto Rico, Italy, Brazil, Mexico
Hoffmann-La Roche

Completed

PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

France, Sweden, Austria, Hungary, Poland, Romania, Slovenia, Croatia, Serbia, Canada, Brazil, Morocco, Mexico, Macedonia, The Former Yugoslav Republic of
Hoffmann-La Roche

Completed

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Hepatitis C, Chronic

Belgium, France, Germany, Italy, Spain, Sweden, United States, Greece, Portugal, Turkey, Switzerland, Canada, United Kingdom, Brazil
Hoffmann-La Roche

Completed

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

United States, Spain, France, Canada, Germany, Austria, Australia, Brazil, United Kingdom, Italy, Mexico, Poland, Puerto Rico
Hoffmann-La Roche

Completed

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

Hepatitis C, Chronic

Australia, France, Italy, Spain, United States, Canada, Germany, Puerto Rico, New Zealand
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
Hoffmann-La Roche

Completed

PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

United States, Puerto Rico
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
ZymoGenetics
Bristol-Myers Squibb

Unknown

Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection (EMERGE)

Hepatitis C, Chronic

Australia, France, Poland, United States, Spain, Germany, Romania, Canada, Austria, Italy, Puerto Rico
Hoffmann-La Roche

Terminated

An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

Hepatitis C, Chronic

France, United States, Canada, New Zealand, Spain, Germany, United Kingdom, Australia, Italy, Brazil, Mexico, Slovakia, Poland, Puerto Rico, Austria
Gilead Sciences

Completed

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

Hepatitis C, Chronic

United States, Spain, Australia, Netherlands, Italy, New Zealand, Germany, United Kingdom, France, Sweden, Canada, Estonia, Poland, Puerto Rico, Austria, Czechia
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C (BASIS)

Hepatitis C Virus (HCV)

Mexico, Korea, Republic of, Czech Republic

3

Subscribe